1 Wallis CJ, Satkunasivam R. Prostate cancer: risk factors – you find what you are looking for. Nat Rev Urol. 2017; 14: 202-4.
2 Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer. 2014; 50: 78-84.
3 Kim TH, Jeong JW, Song JH, Lee KR, Ahn S, Ahn SH, et al. Pharmacokinetics of enzalutamide, an anti-prostate cancer drug, in rats. Arch Pharm Res. 2015; 38: 2076-82.
4 Krauwinkel W, Noukens J, Van Dijk J, Popa S, Ouatas T, De Vries M, et al. A comparison of the pharmacokinetics and safety of enzalutamide in subjects with hepatic impairment and matched healthy subjects. J Clin Pharm Ther. 2017; 42: 268-75.
5 Crona DJ, Milowsky MI, Whang YE. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance. Clin Pharmacol Ther. 2015; 98: 582-9.
6 Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010; 375: 1437-46.
7 Cheng CJ, Tietjen GT, Saucier-Sawyer JK, Saltzman WM. A holistic approach to targeting disease with polymeric nanoparticles. Nat Rev Drug Discov. 2015; 14: 239-47.
8 Chen J, Wu Z, Ding W, Xiao C, Zhang Y, Gao S, et al. SREBP1 siRNA enhance the effect of docetaxel based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant prostate cancer. Theranostics. 2019; 10: 1619-32.
9 Qiang L, Cai Z, Jiang W, Liu J, Tai Z, Li G, et al. A novel macrophage-mediated biomimetic delivery system with NIR-triggered release for prostate cancer therapy. J Nanobiotechnology. 2019; 17: 83.
10 Xia Q, Gong C, Gu F, Wang Z, Hu C, Zhang L, et al. Functionalized multi-walled carbon nanotubes for targeting delivery of immunostimulatory CpG oligonucleotides against prostate cancer. J Biomed Nanotechnol. 2018; 14: 1613-26.
11 Feeney OM, Crum MF, McEvoy CL, Trevaskis NL, Williams HD, Pouton CW, et al. 50 years of oral lipid-based formulations: provenance, progress and future perspectives. Adv Drug Deliv Rev. 2016; 101: 167-94.
12 Wang H, Sun D, Zhao N, Yang X, Shi Y, Li J, et al. Thermo-sensitive graphene oxide-polymer nanoparticle hybrids: synthesis, characterization, biocompatibility and drug delivery. J Mater Chem B. 2014; 2: 1362-70.
13 Xu Z, Zhu S, Wang M, Li Y, Shi P, Huang X. Delivery of paclitaxel using PEGylated graphene oxide as a nanocarrier. ACS Appl Mater Inter. 2015; 7: 1355-63.
14 Yang K, Zhang S, Zhang G, Sun X, Lee ST, Liu Z. Graphene in mice: ultrahigh in vivo tumor uptake and efficient photothermal therapy. Nano Lett. 2010; 10: 3318-23.
15 Li H, Flerens K, Zhang Z, Vanparijs N, Schuijs MJ, Van Steendam K, et al. Spontaneous protein adsorption on graphene oxide nanosheets allowing efficient intracellular vaccine protein delivery. ACS Appl Mater Inter. 2016; 8: 1147-55.
16 Li J, Liang X, Zhang J, Yin Y, Zuo T, Wang Y, et al. Inhibiting pulmonary metastasis of breast cancer based on dual-targeting graphene oxide with high stability and drug loading capacity. Nanomedicine. 2018; 14: 1237-48.
17 Zhang X, Gong C, Akakuru OU, Su Z, Wu A, Wei G. The design and biomedical applications of self-assembled two-dimensional organic biomaterials. Chem Soc Rev. 2019; 48: 5564-95.
18 Song E, Han W, Li C, Cheng D, Li L, Liu L, et al. Hyaluronic acid-decorated graphene oxide nanohybrids as nanocarriers for targeted and pH-responsive anticancer drug delivery. ACS Appl Mater Inter. 2014; 6: 11882-90.
19 Pan Y, Sahoo NG, Li L. The application of graphene oxide in drug delivery. Expert Opin Drug Deliv. 2012; 9: 1365-76.
20 Yeh CY, Hsiao JK, Wang YP, Lan CH, Wu HC. Peptide-conjugated nanoparticles for targeted imaging and therapy of prostate cancer. Biomaterials. 2016; 99: 1-15.
21 Novak TG, Kim J, Song SH, Jun GH, Kim H, Jeong MS, et al. Fast P3HT exciton dissociation and absorption enhancement of organic solar cells by PEG-functionalized graphene quantum dots. Small. 2016; 12: 994-9.
22 Liang RP, Qiu WB, Zhao HF, Xiang CY, Qiu JD. Electrochemiluminescence resonance energy transfer between graphene quantum dots and graphene oxide for sensitive protein kinase and inhibitor sensing. Anal Chim Acta. 2016; 904: 58-64.
23 Yu X, Cheng H, Zhang M, Zhao Y, Qu L, Shi G. Graphene-based smart materials. Nat Rev Mater. 2017; 2: 17046.
24 Shim G, Kim MG, Park JY, Oh YK. Graphene-based nanosheets for delivery of chemotherapeutics and biological drugs. Adv Drug Deliv Rev. 2016; 105: 205-27.
25 Zhao H, Ding R, Zhao X, Li Y, Qu L, Pei H, et al. Graphene-based nanomaterials for drug and/or gene delivery, bioimaging, and tissue engineering. Drug Discov Today. 2017; 22: 1302-17.
26 Tran TH, Nguyen HT, Pham TT, Chol JY, Choi HG, Yong CS, et al. Development of a graphene oxide nanocarrier for dual-drug chemo-phototherapy to overcome drug resistance in cancer. ACS Appl Mater Inter. 2015; 7: 28647-55.
27 Yang K, Feng L, Liu Z. The advancing uses of nano-graphene in drug delivery. Expert Opin Drug Deliv. 2015; 12: 601-12.
28 Thangavel C, Perepelyuk M, Boopathi E, Liu Y, Polischak S, Deshpande DA, et al. Improvement in therapeutic efficacy and reduction in cellular toxicity: introduction of a novel anti-PSMA-conjugated hybrid antiandrogen nanoparticle. Mol Pharm. 2018; 15: 1778-90.
29 Yang D, Feng L, Dougherty CA, Luker KE, Chen D, Cauble MA, et al. In vivo targeting of metastatic breast cancer via tumor vasculature-specific nano-graphene oxide. Biomaterials. 2016; 104: 361-71.
30 Nasrollahi F, Varshosaz J, Khodadadi AA, Lim S, Jahanian-Najafabadi A. Targeted delivery of docetaxel using transferrin/poly(allylaminehydrochloride)-functionalized graphene oxide nanocarrier. ACS Appl Mater Interfaces. 2016; 8: 13282-93.
31 Tian Y, Guo R, Jiao Y, Sun Y, Shen S, Wang Y, et al. Redox stimuli-responsive hollow mesoporous silica nanocarriers for targeted drug delivery in cancer therapy. Nanoscale Horiz. 2016; 1: 480-7.